Qualitative and quantitative composition Galastop® 50 µg ml Oral solution

These losses could be due to the prolactin inhibitory properties of cabergoline in rats. At daily doses of 0.5 mg/kg/day (approximately 19 times the maximum recommended human dose) during the period of organogenesis in the rabbit, cabergoline caused maternotoxicity characterized by a loss of body weight and decreased food consumption. Doses of 4 mg/kg/day (approximately 150 times the maximum recommended human dose) during the period of organogenesis in the rabbit caused an increased occurrence of various malformations.

• Patients should be careful when performing actions which require fast and accurate reaction during treatment initiation.
• This may happen quickly, even before menstrual periods start again.
• You may have increased sexual urges, unusual urges to gamble, or other intense urges while taking cabergoline.
• The study, which was also published in Obstetrics & Gynecology, included the 69 participants who completed a survey on day 4 after an abortion or pregnancy loss at weeks’ gestation, and these differences noted above persisted through day 14.

Women of childbearing potential and breast-feeding woman should not handle the product or should wear disposable gloves when administering the product. Additional supportive treatments should involve restriction of water and carbohydrate intake https://www.tetrion.co.uk/2023/02/01/trenbolone-steroid-understanding-the-risks-and/ and increase exercise. White high-density polyethylene (HDPE) bottles with a child-resistant polypropylene (PP) cap equipped with inner low-density polyethylene (LDPE) desiccant canister containing silica gel.

Warnings for people with certain health conditions

Therefore, this drug should only be used in pregnancy if clearly needed. Examples of drugs that can cause interactions with cabergoline are listed below. History of pulmonary, pericardial and retroperitoneal fibrotic disorders. This is not a complete list of side effects and others may occur.

Related treatment guides

Symptomatic hypotension can occur with cabergoline administration for any indication. Other drugs may affect cabergoline, including prescription and over-the-counter medicines, vitamins, and herbal products. Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

How to use Cabergoline Tablet

This dosage regimen has been demonstrated to be better tolerated than the single dose regimen in women electing to suppress lactation having a lower incidence of adverse events, in particular of hypotensive symptoms. Cabergoline is a dopaminergic ergoline derivative endowed with a potent and long-lasting PRL-lowering activity. It acts by direct stimulation of the D2-dopamine receptors on pituitary lactotrophs, thus inhibiting PRL secretion. In rats the compound decreases PRL secretion at oral doses of 3-25 mcg/kg, and in-vitro at a concentration of 45 pg/ml. In addition, cabergoline exerts a central dopaminergic effect via D2 receptor stimulation at oral doses higher than those effective in lowering serum PRL levels.